1
|
Yanai K, Fujii T, Horiguchi J, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Shirabe K. Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. BMC Cancer 2020; 20:1068. [PMID: 33158432 PMCID: PMC7648287 DOI: 10.1186/s12885-020-07550-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 10/21/2020] [Indexed: 12/02/2022] Open
Abstract
Background S-1 and cyclophosphamide (CPA) can be given orally, and their combination may have great potential for treating metastatic breast cancer (MBC). A phase I study of sequential S-1 and CPA therapy was conducted in patients with MBC; the recommended doses that were determined for this regimen were 80 mg/m2/day for S-1 and 100 mg/m2/day for CPA. We then conducted a phase II study of this oral S-1 and CPA regimen. Methods This was a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy of a sequential S-1 and CPA regimen for MBC. S-1 was administered orally 2×/day for 14 consecutive days, and then CPA was administered orally 2×/day for 14 consecutive days in a repeating 4-week cycle (S-1 for 2 weeks, CPA for 2 weeks). The primary endpoint was the overall response rate (ORR). Secondary endpoints included the overall survival (OS), progression-free survival (PFS), clinical benefit rate (CBR) and safety. Results Thirty-six patients were enrolled in this study. The overall response was complete response in 0 (0%), partial response in 12 (33.3%), stable disease in 12 (33.3%), and progressive disease in 11 (30.1%) patients. The ORR was 33.3% (12/36). The CBR was 66.7% (24/36). The median PFS was 9.5 months (95%CI: 7.8–12.6 months). The median OS was 20.2 months (95%CI: 15.0–25.4 months) Grade 3/4 adverse events included leukopenia in seven patients (19.4%). Dose reductions because of adverse events occurred in 12 patients (33.3%). There was no treatment-related mortality. Conclusion The combination of sequential therapy with S-1 and CPA was tolerable and had efficacy with good disease control. Sequential therapy with S-1 and CPA may be a feasible new treatment option for patients with MBC; however, further study is warranted to explore the efficacy of this therapy. Trial registration JRCT, JRCTs031180296. Registered 2 December 2019 – Retrospectively registered.
Collapse
Affiliation(s)
- Keiko Yanai
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
| | - Takaaki Fujii
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan. .,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
| | - Jun Horiguchi
- Breast Surgery, International University of Health and Welfare, Chiba, Japan
| | - Yuko Nakazawa
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
| | - Sasagu Kurozumi
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Breast Surgery, International University of Health and Welfare, Chiba, Japan
| | - Sayaka Obayashi
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
| | - Reina Yajima
- Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.,Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
| | - Ken Shirabe
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
| |
Collapse
|
2
|
Debled M, Bellera C, Donamaria C, Soubeyran P. Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence? Cancer Treat Rev 2011; 37:590-8. [PMID: 21592672 DOI: 10.1016/j.ctrv.2011.04.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Revised: 04/13/2011] [Accepted: 04/18/2011] [Indexed: 11/16/2022]
Abstract
While the over-representation of the elderly in the breast cancer population is projected to dramatically increase within the next two decades, data on chemotherapy for elderly patients with metastatic breast carcinoma (MBC) remain very limited. The aim of the present study is to investigate whether elderly patients included in clinical studies for MBC are representative of the population seen during usual clinical practice. Firstly, a review of the literature was performed identifying 39 publications about chemotherapy for MBC focusing on elderly patients and we examined patient characteristics in each of these publications. Comparison of the age distribution of patients included in these studies with that of a large cohort of consecutive MBC patients aged 65years who received chemotherapy in our institution over the last ten years (n=573) indicated that trials tend to include relatively younger patients. Furthermore, criteria to assess external validity of the results are seldom reported. Possible ways to improve the applicability of results such as increasing the minimum age for inclusion and the use of CGA are proposed.
Collapse
Affiliation(s)
- Marc Debled
- Department of Medical Oncology, Institut Bergonié, South-West Comprehensive Cancer Center, Bordeaux Cedex, France.
| | | | | | | |
Collapse
|
3
|
Age-related differences in quality of life in cancer patients: a pilot study of a cancer care coordination/home-telehealth program. Cancer Nurs 2007; 30:434-40. [PMID: 18025915 DOI: 10.1097/01.ncc.0000300167.80466.91] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The cancer care dialogues model emphasizes daily telehealth interactions between patients and a care coordinator (a registered nurse serving as a liaison to the oncologist) to assist patients in the management of common chemotherapy-related symptoms at home. We examined the impact of the dialogues on age-related differences in health-related quality of life (HRQOL) among newly diagnosed cancer patients receiving chemotherapy. We assessed HRQOL among 34 patients, including 15 older adults (65 years or older) and 19 younger adults who were followed for 6 months. Older patients consistently reported better HRQOL scores over the treatment period. In multivariate analysis, older patients reported 10.35 points higher in HRQOL (P = .007). In addition, patients who reported no nervousness while undergoing chemotherapy had an 8.60-point increase in HRQOL scores (P = .012). The dialogues model can make important improvement in symptom management and HRQOL, especially in older adults receiving chemotherapy. Older and younger adults with cancer may benefit equally in cancer treatment in a setting with appropriately managed symptoms. The dialogues model offers promising potential for promoting nurses' better understanding of both the patient needs as the patient receives treatment and innovative technologies in patient management.
Collapse
|
4
|
Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy. Eur J Cancer 2007; 43:1514-28. [PMID: 17482454 DOI: 10.1016/j.ejca.2007.03.017] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2007] [Accepted: 03/19/2007] [Indexed: 12/27/2022]
Abstract
As the incidence of invasive breast cancer, mainly developing at older age, is rising, the absolute number of elderly developing metastatic disease is also increasing. In view of improved life expectancy, sociocultural changes and better supportive measures for chemotherapy-induced toxicity, there is an increasing request for the administration of chemotherapy in elderly. At the moment, medical oncologists are still reluctant to use chemotherapy in elderly partly because of concern about increased toxicity and poor tolerability of this patient cohort, and the inability to appropriately select elderly that may benefit from chemotherapy. The question is whether this attitude remains justified. In this review, the current status of clinical research in the area of metastatic breast cancer regarding toxicity and activity of chemotherapy in older breast cancer patients is discussed. Further, data on pharmacokinetics are emphasised as age-related physiologic changes may affect these features with consequences for toxicity and decision-making. Moreover, data on assessment tools trying to characterise the 'functional age' are reviewed. In general, the literature data are scarce and hampered by major limitations, while pharmacokinetic data indicate that a different approach in older breast cancer patients does not always seem justified. To increase our knowledge aiming at optimisation of cancer treatment in elderly, there is a clear necessity for prospective, well-designed studies with emphasis on the particular requirements of older patients and incorporation of pharmacokinetic and -dynamic evaluation of cytotoxic agents used in this specific group. As in other research areas, maximal progress will be achieved by joined efforts of co-operative research groups.
Collapse
Affiliation(s)
- P Hamberg
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, Rotterdam, The Netherlands.
| | | | | |
Collapse
|
5
|
Abstract
The increasing number of elderly people in the world population has led to a parallel increase in the number of older cancer patients, with over 45% of all cancers in Europe occurring in patients >70 years of age. The increasing tendency to use oral chemotherapy is thus of interest in the elderly, given that both elderly patients and their physicians prefer to use less complex and toxic regimens when such treatments have equivalent efficacy to more complex regimens. However, data from studies designed to evaluate these therapies in the elderly are currently limited. Factors that must be considered before prescribing oral agents to this subset of patients include age-related physiological changes affecting clinical pharmacology, adherence, the patient's capability to self-administer medications, and safety issues concerning the older patient and his or her caregivers. The idea that elderly patients may benefit from the introduction of oral chemotherapy is very fashionable, but to date there is no proof that this approach is as effective as intravenous therapy in this age group, particularly since randomised trials are lacking. This review discusses these issues and reviews current information about the use of specific oral chemotherapeutic drugs for major neoplastic diseases in the elderly.
Collapse
Affiliation(s)
- Sara Lonardi
- Medical Oncology Unit, Cancer Center of the Veneto Region - IRCCS, Padova, Italy
| | | | | | | |
Collapse
|
6
|
Kurtz JE, Dufour P. Strategies for improving quality of life in older patients with metastatic breast cancer. Drugs Aging 2002; 19:605-22. [PMID: 12207554 DOI: 10.2165/00002512-200219080-00006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Given both the increase in the mean age of the population of Western countries and the high incidence of breast cancer beyond the age of 65 years, it is evident that breast cancer in older women will be a very common problem for the medical oncologist. Metastatic breast cancer is still not amenable to a cure; therefore quality of life during therapy is an important issue, which until recently has been poorly investigated. Similarly, despite recent advances in breast cancer therapy, physicians have been reluctant to enrol older patients in clinical trials, and there is a lack of data regarding this population. This review focuses on quality-of-life issues during metastatic breast cancer treatment in geriatric patients, comparing the standard therapeutic options and newer approaches. Although first-line endocrine therapy with tamoxifen remains a standard treatment, the newer third-generation aromatase inhibitors provide similar or better efficacy with fewer adverse effects and a better quality of life. It has been a common belief that chemotherapy impairs quality of life, but recent studies in advanced breast cancer have shown that this therapy has a positive effect on quality of life, at least in responders. Consequently, chemotherapy should not be denied to elderly patients with metastatic breast cancer, provided a prior geriatric assessment is performed to evaluate the risk-benefit ratio. New chemotherapy strategies, such as the taxanes and orally administered chemotherapy, represent a very attractive alternative for a better quality of life in elderly patients with metastatic breast cancer.
Collapse
Affiliation(s)
- Jean-Emmanuel Kurtz
- Department of Oncology and Haematology, Hôpitaux Universitaires de Strasbourg, France.
| | | |
Collapse
|